Large multicenter clinical trials, which examined long‐term anti‐VEGF treatment in patients with AMD, also concluded that therapies that block VEGF could have an effect on the development and progression of geographic atrophy (Martin et al, 2012; Grunwald et al, 2014). The gene discussed is VEGFA; the disease is atrophic macular degeneration.